Skip to main content
Clinical Trials/NCT02444533
NCT02444533
Completed
Phase 4

A Phase IV Randomize, Single-Blind, Trial of Liposomal Bupivacaine (EXPAREL®) for Pain Control in Post-Tonsillectomy Patients

Mayo Clinic1 site in 1 country39 target enrollmentMay 2015

Overview

Phase
Phase 4
Intervention
Liposomal Bupivacaine
Conditions
Tonsillectomy
Sponsor
Mayo Clinic
Enrollment
39
Locations
1
Primary Endpoint
Pain Score (Pain Scores on a 0/10 Scale)
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to determine whether liposomal bupivacaine (long acting injectable anesthetic) provides greater post operative pain relief compared to the standard post operative pain regiment for tonsillectomy patients.

Detailed Description

Subjects will be screened in the clinic when being evaluated for indications for tonsillectomy. Once the decision to proceed with tonsillectomy is made, the patient will be given the information on the study, provided time to review the information and interested patients will be consented. There will be two stages in the study. The first will be the operative stage, which includes the injection during the operation. The second stage is the patient participation stage. During this stage, the patient records the amount of oral pain medication usage, oral intake after their procedure, in addition to their pain scores. These scores are recorded and brought back (or mailed in) to the clinic for collection during the follow up visit, approximately 1 month later (patients will keep records for two weeks). The patients will be freed from participation in the study after the one month visit.

Registry
clinicaltrials.gov
Start Date
May 2015
End Date
May 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Daniel L. Price, M.D.

PI

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of recurrent tonsillitis or bilateral tonsillar hypertrophy requiring bilateral tonsillectomy
  • Willing and able to understand and provide written informed consent

Exclusion Criteria

  • Known pregnancy
  • Women who are currently nursing a child
  • History of coagulopathy; such as hemophilia or Von Willebrand disease, or any congenital or acquired bleeding disorder
  • Use of anticoagulation medication during the study, i.e. aspirin, Coumadin, Plavix, or medications similar in class to these medications will exclude the patient from participation
  • Inability to provide informed consent (patients under guardianship)
  • Known hypersensitivity to local anesthetics
  • History of cardiac disease; such as current impaired cardiovascular function, past history of myocardial infarction, congenital heart disease, current cardiac symptoms, i.e. angina, shortness of breath, or chest pain as determined by history or review of the medical record.
  • History of complex pulmonary disease; such as uncontrolled asthma, chronic obstructive pulmonary disease (COPD), or interstitial lung disease as determined by history or review of the medical record.
  • Impaired renal function as documented in the medical record in the last 3 months with a serum creatinine greater than 1.2 mg/dL or glomerular filtration rate \< 60 mL/min/body surface area (BSA) as determined by history or review of the medical record.
  • History of or current hepatic disease as documented by liver function test abnormality in the last 3 months as determined by history or review of the medical record.

Arms & Interventions

Liposomal Bupivacaine

Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy

Intervention: Liposomal Bupivacaine

Outcomes

Primary Outcomes

Pain Score (Pain Scores on a 0/10 Scale)

Time Frame: day of surgery, 14 days after surgery

Subjects recorded pain scores four times a day in a daily pain diary using a Visual Analog Scale with markings from 0 to 10. 0 indicated "no pain" and 10 indicated "worst possible pain"

Pain Medication Usage (Milligrams Used)

Time Frame: 2 weeks after surgery

Subjects recorded pain medication usage in milligrams used of Tylenol, Ibuprofen, and Oxycodone over a 2 week time frame

Oral Intake (Patient Recorded Oral Intake)

Time Frame: 1 week after surgery

Subjects recorded oral intake over one week after surgery

Secondary Outcomes

  • Number of Subjects Experiencing Complications ( Allergic Reaction, Swallowing Dysfunction, Hospital Admission Related to the Study Drug)(4 weeks)
  • Number of Subjects With Post-tonsillectomy Bleeding(4 weeks)

Study Sites (1)

Loading locations...

Similar Trials